Orchestra BioMed Holdings, Inc. (OBIO)

Orchestra BioMed Holdings Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-57.69	-49.12	-33.61	-23.01	-21.36
Depreciation & Amortization	0.3	0.29	0.22	0.18	0.14
Other Amortization	0	0.11	0.16	0.22	-
Loss (Gain) From Sale of Investments	-1.55	-3.8	-1.63	0.29	2.93
Stock-Based Compensation	8.63	7.63	3.41	0.3	0.22
Other Operating Activities	1.83	2.08	2.6	-0.03	0.07
Change in Accounts Receivable	-0.03	-0	0.03	0.05	-0.08
Change in Inventory	-0.1	0.13	-0.21	0	-0.03
Change in Accounts Payable	4.17	0.15	3.35	1.08	-2.61
Change in Unearned Revenue	-2.02	-2.11	-2.86	1.48	-5.17
Change in Other Net Operating Assets	-1.55	-1.47	-0.76	0.03	-0.31
Operating Cash Flow	-47.99	-46.13	-29.29	-19.43	-26.18
Capital Expenditures	-0.18	-0.08	-0.59	-0.27	-0.54
Investment in Securities	50.17	10.77	-63.53	13.5	27.69
Other Investing Activities	-	-	-	-0.21	-0.19
Investing Cash Flow	49.99	10.69	-64.12	13.02	26.97
Long-Term Debt Issued	-	-	10	-	10
Long-Term Debt Repaid	-	-10.85	-6.45	-4	-
Net Debt Issued (Repaid)	-10.85	-10.85	3.55	-4	10
Issuance of Common Stock	15.38	0.25	0.2	0.01	-
Other Financing Activities	-	56.81	-10.33	-	-
Financing Cash Flow	4.53	46.22	103.26	-3.99	10
Net Cash Flow	6.53	10.78	9.85	-10.41	10.78
Free Cash Flow	-48.17	-46.21	-29.88	-19.7	-26.72
Free Cash Flow Margin	-1819.95%	-1674.09%	-845.74%	-	-468.56%
Free Cash Flow Per Share	-1.33	-1.39	-1.99	-9.33	-13.27
Cash Interest Paid	0.02	1.12	1.37	0.39	-
Levered Free Cash Flow	-24.41	-32.17	-10.06	-13.86	-
Unlevered Free Cash Flow	-24.41	-32.28	-10.22	-13.5	-
Change in Net Working Capital	-4.41	7.92	-7.15	0.08	-

Source: S&P Capital IQ. Standard template. Financial Sources.